GLP-1 & Metabolic Health — Latest Articles

GLP-1s Shift Focus: Heart Benefits Emerge for Type 1 Diabetes

A Paradigm Shift in Type 1 Diabetes Care In a development that could redefine therapeutic standards for millions, recent evidence indicates that glucagon-like p...

Untitled

Untitled

Beyond Efficacy: The Real-World Challenges of GLP-1 Adherence

In the rapidly evolving landscape of metabolic health, the arrival of dual GIP/GLP-1 receptor agonists and potent GLP-1 analogues has marked a therapeutic water...

Fda Flags Novo Nordisk Over Glp-1 Safety Reporting Gaps

Fda Flags Novo Nordisk Over Glp-1 Safety Reporting Gaps On March 5, 2026, the U.S. Food and Drug Administration issued a formal warning letter to Novo Nordisk I...

REDEFINE-4: CagriSema Misses Non-Inferiority Against Tirzepatide

Novo Nordisk's Combination Therapy Delivers Strong Weight Loss, Yet Fails Head-to-Head Benchmark In a definitive test of mechanism-driven synergy, Novo Nordisk'...

New Large-Scale Study Links GLP-1 Drugs to Lower Addiction Risk

A Paradigm Shift in Metabolic Health Treatment For years, the medical community and the public have viewed glucagon-like peptide-1 receptor agonists (GLP-1 RAs)...

Mazdutide Surpasses Semaglutide in Head-to-Head Phase 3 Trial

Breakthrough Comparative Data EmergesInnovent Biologics has released compelling top-line results from its DREAMS-3 Phase 3 clinical trial, marking the first dir...

New Data Reveals Lean Mass Loss Linked to GLP-1 Meds

The Hidden Cost of Rapid Weight LossFor years, the primary metric for success with glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 rece...

Boehringer's Survodutide Delivers 16.6% Weight Loss in Phase 3

A New Contender Enters the Glucagon Arena The landscape of anti-obesity therapeutics received a significant jolt on April 28, 2026, when Boehringer Ingelheim un...

FDA Approves Orforglipron: Daily Oral GLP-1 Eliminating Fasting Barriers

New Oral Option Addresses Adherence Hurdles in Metabolic Health The U.S. Food and Drug Administration (FDA) has approved Orforglipron, marketed under the brand...

Retatrutide’s 29% Weight Loss Marks the Rise of Triple Agonists

Setting the Clinical Benchmark for Obesity Pharmacotherapy In December 2025, Eli Lilly announced positive top-line results from its pivotal Phase 3 TRIUMPH-4 tr...